Allergenis claims its assay results are more accurate than other first-line tests and give more details on the severity of immune response.
The proteomics firm currently has two laboratory-developed tests on the market, one for obstructive coronary artery disease and one for risk of heart attack, stroke, or cardiac death.
The approval of Biogen's Alzheimer's disease treatment in June was seen as an important regulatory development for companies developing tests.
The firm measures three proteins and inputs them into an algorithm to determine whether a patient will have a severe reaction to the SARS-CoV-2 virus.
The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.